United States Patent 7,857,977: Scope, Claims, Expiration and Patent Landscape for Ferric Pyrophosphate Dialysis Solutions

U.S. Patent No. 7,857,977 protects a specific dialysis formulation and process combining ferric pyrophosphate with bicarbonate solution, storage in a polyolefin container, and a stability requirement of at least 48 hours. The patent is narrower than a general ferric pyrophosphate anemia patent because infringement requires the claimed bicarbonate, packaging, stability, and dialysis-use features.

The patent’s commercial relevance is tied to intradialytic iron delivery products, particularly Rockwell Medical’s Triferic product family. Its principal patent risk has historically concerned ferric pyrophosphate incorporation into bicarbonate concentrate rather than injectable iron products such as iron sucrose, ferric gluconate, or ferumoxytol.

What does U.S. Patent 7,857,977 cover?

The patent covers two claim categories:

A packaged bicarbonate solution containing dissolved ferric pyrophosphate.
A dialysis process using that solution to form a ferric-pyrophosphate-containing dialysate.

The independent claims require the following elements:

Claim feature	Claim 1 packaged solution	Claim 3 dialysis process
Bicarbonate solution	Required	Required
Ferric pyrophosphate dissolved in solution	Required	Required
Therapeutic anemia or iron-deficiency purpose	Required	Required
Reduction of recombinant erythropoietin dose as an alternative purpose	Required	Required
Polyolefin container or polyolefin liner	Required	Required
Ferric pyrophosphate concentration unchanged for at least 48 hours	Required	Required
Combination with water and dialysis concentrate	Not expressly required in the product claim	Required
Dialysis treatment of a patient	Intended use tied to claim language	Required
High-density polyethylene	Dependent claim 2	Dependent claim 4
Dialysate iron concentration of 2-12 micrograms/dL	Not included	Dependent claim 5

The claims do not broadly cover every ferric pyrophosphate formulation, every iron-containing dialysate, or every dialysis anemia treatment.

How broad is claim 1 of Patent 7,857,977?

Claim 1 is a combination product claim. A potentially infringing product must satisfy all material limitations:

It must be a bicarbonate solution suitable for dialysis.
Ferric pyrophosphate must be dissolved in that solution.
The amount must be therapeutically effective for anemia, iron deficiency, or reduction of recombinant erythropoietin use.
The solution must be contained in a polyolefin container or a container with a polyolefin liner.
The solution must remain sufficiently stable so that ferric pyrophosphate concentration remains unchanged for at least 48 hours after preparation.

The claim is structurally narrow because the packaging limitation is mandatory. A ferric pyrophosphate bicarbonate concentrate stored in glass, stainless steel, a non-polyolefin polymer, or another container would not literally satisfy the container limitation.

The stability limitation is also material. A formulation may contain ferric pyrophosphate and be suitable for dialysis but fall outside claim 1 if the ferric pyrophosphate concentration changes during the claimed 48-hour period.

The phrase "remains unchanged" creates a potential claim-construction issue. In commercial testing, concentration is rarely literally identical at every measurement point. Courts would likely interpret the term in light of the specification, analytical method, and any disclosed tolerance or assay variation. The prosecution history and specification are important to determine whether "unchanged" means analytically constant, substantially constant, or within a defined range.

What does claim 3 add to the patent scope?

Claim 3 is a process claim that requires more steps than claim 1. The process must include:

Preparing a bicarbonate solution.
Dissolving ferric pyrophosphate in that solution.
Storing the solution in a polyolefin container or liner.
Maintaining the ferric pyrophosphate concentration for at least 48 hours.
Combining the solution with a predetermined amount of water and a predetermined dialysis concentrate.
Forming a dialysate.
Dialyzing a patient with that dialysate.

This claim is directed to a complete dialysis-treatment workflow. A supplier could potentially avoid literal infringement of the process claim if it sells the bicarbonate concentrate but does not perform, direct, or control the downstream dilution and dialysis steps. The product claim, however, may still create exposure for the packaged concentrate itself.

Claim 3 also requires that the ferric pyrophosphate-containing bicarbonate solution be stored before dialysis use. A product mixed immediately before use may present a different infringement analysis if the required storage period or 48-hour stability limitation is absent.

What does claim 5 protect?

Claim 5 narrows claim 3 to a dialysate iron concentration of approximately 2 to 12 micrograms per deciliter.

Parameter	Claimed range
Minimum iron concentration	About 2 micrograms/dL
Maximum iron concentration	About 12 micrograms/dL
Measurement point	The formed dialysate

The location of measurement matters. The range applies to the final dialysate, not necessarily the bicarbonate concentrate. A concentrate can have a substantially higher iron concentration before dilution and still fall within claim 5 if the final dialysate is within the stated range.

The words "about 2" and "about 12" introduce customary numerical flexibility, but the permissible range would depend on the specification, prosecution history, assay precision, and ordinary meaning in the dialysis field.

What formulations are protected by Patent 7,857,977?

The patent is directed to ferric pyrophosphate dissolved in bicarbonate solution for delivery through the dialysate. The formulation must be stable in polyolefin packaging for at least 48 hours.

The patent therefore has greatest relevance to:

Liquid bicarbonate concentrates containing ferric pyrophosphate.
Bicarbonate solutions packaged in high-density polyethylene.
Dialysate systems that deliver iron continuously or intermittently during hemodialysis.
Products designed to reduce intravenous iron administration or recombinant erythropoietin requirements.
Premixed or prefilled bicarbonate components used with dialysis concentrates.

The patent is less directly relevant to:

Ferric pyrophosphate administered intravenously outside the dialysate.
Iron sucrose, sodium ferric gluconate, ferric carboxymaltose, or ferumoxytol.
Dry powders that do not contain a bicarbonate solution until immediately before use.
Dialysate products without ferric pyrophosphate.
Bicarbonate solutions packaged in containers lacking a polyolefin contact surface.
Formulations that do not maintain the claimed stability profile.

Does the patent require high-density polyethylene?

No. High-density polyethylene is required only by dependent claims 2 and 4.

The independent claims cover a broader class of containers:

Polyolefin containers generally.
Containers with a polyolefin liner.

High-density polyethylene is one species within the broader polyolefin category. Other polyolefin materials may include low-density polyethylene, polypropylene, and related polyolefin structures, depending on the claim interpretation and product construction.

A formulation in a high-density polyethylene container would fall within the narrower dependent claims if the remaining limitations are satisfied. A formulation in polypropylene could potentially satisfy the independent claim even if it does not satisfy the high-density polyethylene limitation.

What are the principal noninfringement positions?

A competing product could focus on one or more of the following limitations:

Potential design-around	Relevance
Use a non-polyolefin container	Removes a central product and process limitation
Use a glass container	May avoid claims 1-4 if no polyolefin liner is present
Use a dry ferric pyrophosphate composition	May avoid the requirement that ferric pyrophosphate be dissolved in bicarbonate solution
Mix ferric pyrophosphate immediately before dialysis	May challenge the storage and 48-hour stability limitations
Use a different iron compound	Avoids ferric pyrophosphate limitations
Deliver iron intravenously rather than through dialysate	Avoids the claimed dialysate architecture
Use a final dialysate concentration outside approximately 2-12 micrograms/dL	Potentially avoids claim 5
Demonstrate concentration change during the relevant period	Challenges the stability limitation
Separate the bicarbonate and iron components until use	May avoid the packaged bicarbonate-solution claim

The doctrine of equivalents could limit the effectiveness of some design-arounds. A material substitution would be evaluated based on function, way, and result, as well as prosecution-history estoppel.

When did Patent 7,857,977 expire?

U.S. Patent No. 7,857,977 issued on December 28, 2010. Its term is governed by the 20-year rule measured from the earliest effective nonprovisional priority date, subject to patent-term adjustment, terminal disclaimers, and any other statutory adjustments.[1]

Public patent records associate the patent family with an early-2000s priority position and a nominal term ending in the mid-2020s. The effective expiration date must be confirmed from the USPTO patent-term data, including any patent-term adjustment. Patent 7,857,977 should not be assessed solely from its issue date.

If the patent’s statutory term has ended, the issued claims no longer create an ordinary U.S. infringement barrier. Later continuation, divisional, or related patents may still matter if they contain separately enforceable claims directed to the same commercial product.

What is the Orange Book status of Patent 7,857,977?

Patent 7,857,977 should be analyzed separately from Orange Book-listed patents.

The Orange Book lists patents submitted by an NDA holder for an approved drug product. A patent may be technically relevant to a commercial dialysis product without appearing in the Orange Book. Listing depends on the approved NDA, the drug product, the patent’s relationship to the approved labeling or dosage form, and the sponsor’s submission.

The key distinction is:

Issue	Patent 7,857,977 analysis
Patent subject matter	Dialysis bicarbonate solution, packaging, stability, and use
Orange Book relevance	Depends on the specific NDA and listing submission
Automatic Orange Book protection	No
Protection of unlisted commercial technology	Possible under ordinary patent law if the patent is unexpired
Paragraph IV relevance	Applies only if an ANDA applicant challenges a listed patent associated with the relevant NDA

Later patents associated with Triferic or Triferic AVNU may be more important for current Orange Book exposure than Patent 7,857,977. The relevant analysis requires matching the patent number to the approved product and current FDA listing data.[2]

Which companies are associated with the ferric pyrophosphate dialysis market?

Rockwell Medical is the principal company associated with ferric pyrophosphate delivered through dialysate. Its Triferic products were developed to provide iron during hemodialysis and reduce the need for conventional intravenous iron replacement.

The competitive landscape includes:

Company or product category	Iron strategy	Relationship to Patent 7,857,977
Rockwell Medical Triferic	Ferric pyrophosphate delivered through dialysate	Directly aligned with the claimed technology
Rockwell Medical Triferic AVNU	Ferric pyrophosphate dialysis product	Requires separate patent and regulatory review
Venofer, marketed by CSL Vifor	Iron sucrose, intravenous administration	Different active ingredient and delivery route
Ferrlecit, marketed by Sanofi	Sodium ferric gluconate, intravenous administration	Different active ingredient and delivery route
Injectafer, marketed by CSL Vifor	Ferric carboxymaltose, intravenous administration	Different active ingredient and delivery route
Feraheme, marketed by AMAG and later affiliates	Ferumoxytol, intravenous administration	Different active ingredient and delivery route
Dialysis providers and private-label manufacturers	May use or distribute dialysate systems	Exposure depends on product composition and supply role

The principal competitive distinction is route of administration. Patent 7,857,977 targets iron delivery through the dialysate, not the broad market for parenteral iron drugs.

What patent families are likely to matter after Patent 7,857,977?

A freedom-to-operate review should not stop with the issued claims quoted in the question. The relevant family and adjacent patent groups may include:

Ferric pyrophosphate composition patents.
Bicarbonate concentrate formulation patents.
Container and material-compatibility patents.
Stability and shelf-life patents.
Dialysis iron-delivery method patents.
Triferic and Triferic AVNU product patents.
Manufacturing-process patents for ferric pyrophosphate.
Labeling and method-of-use patents directed to anemia management.
Continuation patents with narrower concentration, packaging, or dosage claims.

A continuation can preserve commercial leverage even after an earlier patent expires. The operative question is whether a later patent claims the accused product’s formulation, manufacturing method, container, concentration, or labeled use.

What patent litigation and Paragraph IV risks apply?

The disclosed claims are more likely to create litigation risk in a product-specific patent dispute than in a conventional generic-drug dispute.

A Paragraph IV challenge would require:

An approved reference product with a listed patent.
An ANDA applicant seeking approval of a therapeutically equivalent product.
A certification that the listed patent is invalid, unenforceable, or not infringed.
Notice to the patent owner and NDA holder.
Potential 30-month FDA approval stay under the Hatch-Waxman framework.[3]

For a dialysis concentrate or specialty dialysis product, the regulatory pathway may not fit the standard small-molecule ANDA model in the same way as a conventional tablet. Product classification, NDA status, formulation similarity, and the FDA’s designated reference product are decisive.

Potential litigation theories would likely focus on:

Whether the accused container is a polyolefin container or has a polyolefin liner.
Whether ferric pyrophosphate is dissolved in the bicarbonate solution.
Whether concentration remains unchanged for at least 48 hours.
Whether the product is used to make dialysate.
Whether the final iron concentration falls within the claim 5 range.
Whether the asserted claim is anticipated or obvious based on earlier dialysis iron literature.
Whether the therapeutic-purpose language limits the claims or merely states intended use.

How strong is the patent estate?

Patent 7,857,977 has meaningful historical strength against products that copy the claimed commercial architecture: ferric pyrophosphate in a liquid bicarbonate concentrate, stored in polyolefin packaging, and used to prepare iron-containing dialysate.

Its strength is lower against products that change the delivery format or packaging. The independent claims depend on several cumulative elements, which limits breadth but also provides multiple technical infringement issues for a copied product.

Risk factor	Assessment
Coverage of ferric pyrophosphate dialysis delivery	Strong
Coverage of all dialysis iron products	Weak
Coverage of injectable iron products	None or minimal
Packaging-specific coverage	Strong where polyolefin packaging is used
Stability limitation	Potentially difficult to prove but commercially important
Coverage of dry or point-of-use formulations	Limited
Coverage of non-polyolefin packaging	Limited
Current standalone value	Dependent on unexpired term and related continuations
Orange Book leverage	Product- and NDA-specific
Design-around potential	Moderate to high

What generic or competitor launch scenarios exist?

A competing launch could follow several paths:

Direct copy

A product using the same active ingredient, bicarbonate vehicle, polyolefin packaging, storage profile, and dialysis concentration would present the highest infringement risk.

Packaging design-around

A non-polyolefin container could reduce exposure to the literal container limitation, although liners, multilayer structures, closures, and manufacturing components would require analysis.

Point-of-use formulation

A product supplied as separate components and mixed shortly before dialysis could challenge the packaged-solution and 48-hour storage limitations. The process claims would still require analysis of the actual treatment workflow.

Alternative iron delivery

Intravenous iron, iron added directly to the extracorporeal circuit, or a different iron complex would generally avoid the central ferric-pyrophosphate bicarbonate combination.

Concentration design-around

A final dialysate iron concentration outside the approximate 2-12 microgram/dL range could avoid claim 5 but would not avoid claims 1 or 3 if those claims are otherwise satisfied.

Key Takeaways

Patent 7,857,977 is a combination patent, not a broad patent on all iron therapy for dialysis patients.
Its core combination is ferric pyrophosphate dissolved in bicarbonate solution and stored in polyolefin packaging.
The 48-hour concentration-stability requirement is a central limitation.
Claims 1 and 3 are broader than claims 2, 4, and 5 because the dependent claims add high-density polyethylene or a specific dialysate iron range.
Claim 3 requires a complete process ending in dialysis treatment.
High-density polyethylene is not required by the independent claims.
Injectable iron products such as iron sucrose and ferric gluconate generally fall outside the claim architecture.
Orange Book significance depends on the specific FDA-approved product and current listing, not merely on the technical relevance of the patent.
Current commercial risk depends heavily on the patent’s effective expiration date and any continuation or related patents.
A copied Triferic-type product presents substantially greater risk than a dry, point-of-use, non-polyolefin, or non-ferric-pyrophosphate product.

Frequently Asked Questions

Does Patent 7,857,977 cover ferric pyrophosphate itself?

No. The claims require ferric pyrophosphate in a bicarbonate solution configured for dialysis use. They do not claim every composition containing ferric pyrophosphate.

Can a product avoid the patent by using polypropylene instead of high-density polyethylene?

Possibly for the high-density-polyethylene dependent claims, but not necessarily for the independent claims. Polypropylene may still fall within the broader polyolefin limitation.

Does a 48-hour shelf life automatically satisfy the stability limitation?

No. The relevant issue is whether ferric pyrophosphate concentration remains unchanged during the claimed period, not merely whether the product remains usable for 48 hours.

Is a dialysis product with iron sucrose covered by these claims?

Generally no. The claims require ferric pyrophosphate, not iron sucrose or another iron complex.

Are related continuation patents more important than Patent 7,857,977?

They may be. A continuation can contain claims directed to the same commercial product but with different limitations involving formulation, packaging, concentration, manufacturing, or method of use.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term expiration principles. USPTO.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. FDA.
United States Patent and Trademark Office. (2010). U.S. Patent No. 7,857,977: Ferric pyrophosphate compositions and methods of use. USPTO.
Rockwell Medical, Inc. (n.d.). Triferic and Triferic AVNU product information. Rockwell Medical.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	POWDER;INTRAVENOUS	208551-001	Apr 25, 2016		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2550493	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,857,977

Which drugs does patent 7,857,977 protect, and when does it expire?

Summary for Patent: 7,857,977